TABLE 1.
Study cohort: clinical data
| Patient | Age (yr) | Sexa | Duration of HIV infection (yr) | Yr of suppressive ART | Viral load (copies/ml) | CD4 count (cells/μl) | ART status |
|---|---|---|---|---|---|---|---|
| MP106 | 37 | M | 0.1 | 0 | 160,000 | 501 | Treatment naive |
| MP140 | 23 | M | 0.08 | 0 | 360,000 | 427 | Treatment naive |
| MP119 | 23 | M | 1.3 | 0 | 13,000 | 498 | Treatment naive |
| MP124 | 46 | F | 0.06 | 0 | 510,000 | 468 | Treatment naive |
| MP117 | 51 | M | 5.42 | 0 | 54,000 | 504 | Treatment naive |
| MP125 | 35 | M | 0.16 | 0 | 17,000 | 511 | Treatment naive |
| MP118 | 29 | M | 0.06 | 0 | 14,000 | 538 | Treatment naive |
| SA150 | 53 | M | 10 | 0 | 6,900 | 578 | Treatment naive |
| SA143 | 37 | M | 0.3 | 0 | 25,000 | 704 | Treatment naive |
| MP129 | 44 | M | 14.85 | 14.71 | <20 | 928 | ART treated |
| MP068-1 | 45 | M | 3.33 | 3 | <20 | 928 | ART treated |
| MP136 | 44 | M | 7.5 | 6 | <20 | 732 | ART treated |
| MP123 | 61 | M | 9.25 | 9 | <20 | 1,270 | ART treated |
| MP137 | 39 | M | 3.59 | 2.84 | 24 | 700 | ART treated |
| MP064 | 36 | M | 7.88 | 4.49 | <20 | 719 | ART treated |
| MP141 | 31 | M | 11.56 | 1.5 | <20 | 558 | ART treated |
| MP094 | 47 | M | 8 | 8 | <20 | 451 | ART treated |
| MP058 | 46 | F | 10.86 | 10 | <20 | 666 | ART treated |
| MP082 | 53 | M | 22.45 | 8 | <20 | 1,236 | ART treated |
| MP096 | 54 | F | 18 | 13 | <20 | 1,253 | ART treated |
| MP103 | 41 | M | 1.62 | 1.16 | <20 | 217 | ART treated |
| MP068-2 | 47 | M | 5.12 | 5 | <20 | 487 | ART treated |
| MP060 | 42 | M | 21 | 8 | <20 | 786 | ART treated |
| MP067 | 41 | M | 14.01 | 14 | <20 | 609 | ART treated |
| MP072 | 47 | M | 18 | 2 | <20 | 614 | ART treated |
| MP070 | 55 | M | 7.06 | 2 | <20 | 615 | ART treated |
| MP100 | 36 | F | 13.06 | 10 | <20 | 643 | ART treated |
| MP145 | 39 | M | 8.35 | 4 | <20 | 820 | ART treated |
a
M, male; F, female.